SCHEMBL9850093

SCHEMBL9850093

O=C(Cl)c1ccccc1NS(=O)(=O)c1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.60
▸ TSHR P16473 1/20 0.60
▸ ALDH1A1 P00352 3/20 0.56
▸ KDM4E B2RXH2 3/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ METAP2 P50579 2/20 0.55
▸ MEN1 O00255 5/20 0.54
▸ POLB P06746 1/20 0.54
▸ KCNA5 P22460 1/20 0.53
▸ LMNA P02545 2/20 0.52
▸ GAA P10253 1/20 0.52
▸ CYP3A4 P08684 1/20 0.52
▸ CYP2D6 P10635 1/20 0.52
▸ CYP2C9 P11712 1/20 0.52
▸ HPGD P15428 1/20 0.52
▸ CRHBP P24387 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ HTT P42858 1/20 0.52
▸ CRHR2 Q13324 1/20 0.52
▸ NOD2 Q9HC29 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11010265 0.89 CCR2 (0.61) KMT2AALDH1A1KDM4EMETAP2MEN1
SCHEMBL2499921 0.87 LMNA (0.67) KMT2ATSHRALDH1A1KDM4ESMN1; SMN2
SCHEMBL1466906 0.86 ALDH1A1 (0.72) KMT2ATSHRALDH1A1KDM4EMETAP2
SCHEMBL4801356 0.84 LMNA (0.69) KMT2ATSHRALDH1A1KDM4ESMN1; SMN2
SCHEMBL7531862 0.83 KMT2A (0.69) KMT2ATSHRALDH1A1KDM4ESMN1; SMN2
SCHEMBL2478988 0.83 ERBB2 (0.67) METAP2KCNA5LMNAHTTACLY
SCHEMBL10487706 0.83 KMT2A (0.60) KMT2ATSHRALDH1A1KDM4ESMN1; SMN2
SCHEMBL3416851 0.83 KDM4E (0.60) KMT2ATSHRALDH1A1KDM4ESMN1; SMN2
SCHEMBL2201197 0.83 ELANE (0.64) KMT2ATSHRALDH1A1KDM4ESMN1; SMN2
SCHEMBL12200971 0.82 METAP2 (0.79) KMT2ATSHRALDH1A1METAP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7332608-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-19 — — US disclosed
US-7332608-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-19 — — US disclosed
US-7235690-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-26 — — US disclosed
US-7235690-B2 Anthranilamides and methods of their use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-26 — — US disclosed
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-24 — — US disclosed
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-05-24 — — US disclosed
US-5053325-A 2-hydrogen bond donating group-substituted benzoyl acetanilides KONICA CORPORATION (JP) 1991-10-01 — — US disclosed
EP-0422505-A1 Silver halide color photographic light-sensitive material KONICA CORPORATION (JP) 1991-04-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117807-A1 ANTHRANILAMIDES AND METHODS OF THEIR USE KCNH1, KCNH2, KCNJ2 KMT2A 587/4885TSHR 1612/4885ALDH1A1 1053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback